Aclaris Therapeutics Inc (ACRS) - Total Liabilities
Based on the latest financial reports, Aclaris Therapeutics Inc (ACRS) has total liabilities worth $55.43 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Aclaris Therapeutics Inc strategic investment ratio to see how much of total assets are deployed in long-term investments.
Aclaris Therapeutics Inc - Total Liabilities Trend (2013–2024)
This chart illustrates how Aclaris Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Aclaris Therapeutics Inc balance sheet assets.
Aclaris Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Aclaris Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hiyes International Co Ltd
TW:2348
|
Taiwan | NT$37.42 Billion |
|
TVZone Media Co Ltd
SHG:603721
|
China | CN¥346.40 Million |
|
Plasson Indus
TA:PLSN
|
Israel | ILA989.96 Million |
|
Zhuhai Winbase International Chemical Tank Terminal Co Ltd
SHE:002492
|
China | CN¥523.64 Million |
|
Ferm. Casino Mun. Canne
PA:FCMC
|
France | €170.47 Million |
|
ENDOMINES FINLAND OYJ EO1
F:H13
|
Germany | €35.60 Million |
|
Alltek Technology Corp
TW:3209
|
Taiwan | NT$17.14 Billion |
|
Siward Crystal Technology Co Ltd
TW:2484
|
Taiwan | NT$901.23 Million |
Liability Composition Analysis (2013–2024)
This chart breaks down Aclaris Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See ACRS equity to assets ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.92 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.46 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.32 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Aclaris Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Aclaris Therapeutics Inc (2013–2024)
The table below shows the annual total liabilities of Aclaris Therapeutics Inc from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $64.77 Million | +61.02% |
| 2023-12-31 | $40.23 Million | -29.40% |
| 2022-12-31 | $56.98 Million | +5.76% |
| 2021-12-31 | $53.87 Million | +62.58% |
| 2020-12-31 | $33.13 Million | +16.73% |
| 2019-12-31 | $28.39 Million | -53.04% |
| 2018-12-31 | $60.44 Million | +231.24% |
| 2017-12-31 | $18.25 Million | +176.68% |
| 2016-12-31 | $6.59 Million | +324.12% |
| 2015-12-31 | $1.55 Million | -95.92% |
| 2014-12-31 | $38.13 Million | +63.17% |
| 2013-12-31 | $23.37 Million | -- |
About Aclaris Therapeutics Inc
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. Its … Read more